Compare AU & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AU | QGEN |
|---|---|---|
| Founded | 1944 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3B | 8.7B |
| IPO Year | 2023 | 1998 |
| Metric | AU | QGEN |
|---|---|---|
| Price | $96.21 | $42.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $119.00 | $45.76 |
| AVG Volume (30 Days) | 2.4M | ★ 2.4M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | 3.94% | ★ 7.17% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.71 | $8.18 |
| Revenue Next Year | $2.89 | $5.71 |
| P/E Ratio | ★ $23.93 | $24.01 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $52.05 | $32.53 |
| 52 Week High | $129.14 | $57.82 |
| Indicator | AU | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.77 | 58.85 |
| Support Level | $89.75 | $42.82 |
| Resistance Level | $98.06 | $44.03 |
| Average True Range (ATR) | 3.19 | 0.87 |
| MACD | 1.75 | -0.01 |
| Stochastic Oscillator | 81.66 | 55.93 |
Anglogold Ashanti PLC is an independent gold mining company. It has a diversified asset portfolio, including production from operations in eight countries (Argentina, Australia, Brazil, Egypt, Ghana, Guinea, the DRC, and Tanzania), supported by greenfield projects in the United States and Colombia. The company's main product is gold, which once mined, is processed into dore (unrefined gold bars) on site and then dispatched to precious metals refineries. Geographically, Anglogold generates maximum revenue from its operations in Africa (comprising operations at Kibali, Iduapriem, Obuasi, Siguiri, Geita, and Sukari mines), followed by Australia (including Sunrise Dam and Tropicana), and the Americas (comprising Cerro Vanguardia, AngloGold Ashanti Mineracao, and Serra Grande operations).
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).